Sebastiao Nunes Martins Filho

Sebastiao Nunes Martins Filho

Auto-generated profile, based on publicly available information

Sebastiao Nunes Martins Filho

Departamento de Patologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
TTTakuma Tsuchida
Takuma Tsuchida
YLYoungmin A. Lee
Youngmin A. Lee
NFNaoto Fujiwara
Naoto Fujiwara
MYMaria Ybanez
Maria Ybanez
BABrittany Allen
Brittany Allen
SFScott Laurence Friedman
Scott Laurence Friedman

1 March 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RSRuoshi Shi
Ruoshi Shi
NRNikolina Radulovich
Nikolina Radulovich
CNChristine Ng
Christine Ng
NLNi Liu
Ni Liu
HNHirotsugu Notsuda
Hirotsugu Notsuda
MTMing Tsao
Ming Tsao
Purpose: Non–small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide. There is an unmet need to develop novel clinically relevant models of NSCLC to accelerate identification of drug targets and our understanding of the disease. Experimental Design: Thirty surgically resected NSCLC primary patient tissue and 35 previously established patient-derived xenograft (PDX) models were processed for organoid culture establishment. Organoids were histologically and molecularly characterized by cytology and histology, exome sequencing, and RNA-sequencing analysis. Tumorigenicity was assessed through subcutaneous injection of organoids in NOD/SCID mice. Organoids were subjected to drug testing using EGFR, FGFR, and MEK-targeted therapies. Results: We have identified cell culture conditions favoring the establishment of short-term and long-term expansion of NSCLC organoids derived from primary lung patient and PDX tumor tissue. The NSCLC organoids recapitulated the histology of the patient and PDX tumor. They also retained tumorigenicity, as evidenced by cytologic features of malignancy, xenograft formation, preservation of mutations, copy number aberrations, and gene expression profiles between the organoid and matched parental tumor tissue by whole-exome and RNA sequencing. NSCLC organoid models also preserved the sensitivity of the matched parental tumor to targeted therapeutics, and could be used to validate or discover biomarker–drug combinations. Conclusions: Our panel of NSCLC organoids closely recapitulates the genomics and biology of patient tumors, and is a potential platform for drug testing and biomarker validation.

10 November 2017 in Frontiers in Medicine
Verified
Journal Article
Open access
SMSebastiao N. Martins-Filho
Sebastiao N. Martins-Filho
CPCaterina Paiva
Caterina Paiva
RARaymundo Soares Azevedo
Raymundo Soares Azevedo
VAVenancio Avancini Ferreira Alves
Venancio Avancini Ferreira Alves
Background: Histological grading typically reflects the biological behavior of solid tumors, thus providing valuable prognostic information. This is also expected in Hepatocellular Carcinoma (HCC), although limited access to biopsy samples and a lack of standardization might hinder its full predictive value in this cancer. Objectives: In order to better understand the current practices of histological grading in HCC, we examined the latest publications addressing its impact on the outcome of patients following surgical treatment. Methods: We searched the PubMed (MEDLINE) database under the headings “hepatocellular carcinoma”, “grade OR grading”, and “prognosis”. Qualitative and quantitative assessment of publications was performed according to the reference they used to grade their tumors (e.g. Edmondson-Steiner, World Health Organization). Results: We reviewed a total of 216 articles: 114 enclosed adequate information and were included herein. Among those, we found divergences as well as inaccuracies in the histological grade assessment of this cancer, which might have led to a non-standardized grade distribution, with further impact on data analysis. Nevertheless, in most of them, poor tumor differentiation correlated with worse prognosis, expressed by lower overall and/or disease-free survival. Conclusions: While histological grading of HCC has an important prognostic role, there is an unsatisfactory heterogeneity on the microscopic assessment of this tumor, urging for a movement towards standardization.

9 April 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
ILIsmail Labgaa
Ismail Labgaa
CVCarlos Villacorta-Martin
Carlos Villacorta-Martin
DDDelia D’aVola
Delia D’aVola
ACAmanda J. Craig
Amanda J. Craig
JFJohann von Felden
Johann von Felden
AVAugusto Villanueva
Augusto Villanueva

1 August 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DDDelia D’avola
Delia D’avola
CVCarlos Villacorta-Martin
Carlos Villacorta-Martin
SMSebastiao N. Martins-Filho
Sebastiao N. Martins-Filho
ACAmanda Craig
Amanda Craig
ILIsmail Labgaa
Ismail Labgaa
AVAugusto Villanueva
Augusto Villanueva
Patients with hepatocellular carcinoma (HCC) release tumor cells to the bloodstream, which can be detected using cell surface markers. Despite numerous reports suggest a direct correlation between the number of circulating tumor cells (CTCs) and poor clinical outcomes, few studies have provided a thorough molecular characterization of CTCs. Due to the limited access to tissue samples in patients at advanced stages of HCC, it is crucial to develop new technologies to identify HCC cancer drivers in routine clinical conditions. Here, we describe a method that sequentially combines image flow cytometry and high density single-cell mRNA sequencing to identify CTCs in HCC patients. Genome wide expression profiling of CTCs using this approach demonstrates CTC heterogeneity and helps detect known oncogenic drivers in HCC such as IGF2. This integrated approach provides a novel tool for biomarker development in HCC using liquid biopsy.

1 May 2019 in Neoplasia
Verified
Journal Article
Open access
JHJing Hao
Jing Hao
CZCédric Zeltz
Cédric Zeltz
MPMelania Pintilie
Melania Pintilie
QLQuan Li
Quan Li
SSShingo Sakashita
Shingo Sakashita
RNRoya Navab
Roya Navab
Carcinoma-associated fibroblasts (CAFs) are abundant stromal cells in tumor microenvironment that are critically involved in cancer progression. Contrasting reports have shown that CAFs can have either pro- or antitumorigenic roles, indicating that CAFs are functionally heterogeneous. Therefore, to precisely target the cancer-promoting CAF subsets, it is necessary to identify specific markers to define these subpopulations and understand their functions. We characterized two CAFs subsets from 28 non-small cell lung cancer (NSCLC) patient tumors that were scored and classified based on desmoplasia [mainly characterized by proliferating CAFs; high desmoplastic CAFs (HD-CAF; n = 15) and low desmoplastic CAFs (LD-CAF; n = 13)], which is an independent prognostic factor. Here, for the first time, we demonstrate that HD-CAFs and LD-CAFs show different tumor-promoting abilities. HD-CAFs showed higher rate of collagen matrix remodeling, invasion, and tumor growth compared to LD-CAFs. Transcriptomic analysis identified 13 genes that were differentially significant (fold ≥1.5; adjusted P value < .1) between HD-CAFs and LD-CAFs. The top upregulated differentially expressed gene, ST8SIA2 (11.3 fold; adjusted P value = .02), enhanced NSCLC tumor cell invasion in 3D culture compared to control when it was overexpressed in CAFs, suggesting an important role of ST8SIA2 in cancer cell invasion. We confirmed the protumorigenic role of ST8SIA2, showing that ST8SIA2 was significantly associated with the risk of relapse in three independent NSCLC clinical datasets. In summary, our studies show that functional heterogeneity in CAF plays key role in promoting cancer cell invasion in NSCLC.